It was originally mistaken for juvenile rheumatoid arthritis. The bacterium involved was first described in 1981 by Willy Burgdorfer. Chronic symptoms following treatment are known as "post-treatment Lyme disease syndrome" (PTLDS). PTLDS is different from chronic Lyme disease, a term no longer supported by scientists and used in different ways by different groups. Some healthcare providers claim that PTLDS is caused by persistent infection but this is not believed to be true because no evidence of persistent infection can be found after standard treatment.No human vaccines for Lyme disease are currently available, although research is ongoing. Multiple vaccines are available for the prevention of Lyme disease in dogs. Signs and symptoms
Lyme disease can affect several body systems and produce a broad range of symptoms. Not everyone with Lyme disease has all of the symptoms and many of the symptoms are not specific to Lyme disease but can occur with other diseases as well.The incubation period from infection to the onset of symptoms is usually one to two weeks but can be much shorter (days) or much longer (months to years). Lyme symptoms most often occur from May to September in the northern hemisphere because the nymphal stage of the tick is responsible for most cases. Asymptomatic infection exists but occurs in less than 7% of infected individuals in the United States. Asymptomatic infection may be much more common among those infected in Europe. Early localized infection
Early localized infection can occur when the infection has not yet spread throughout the body.
The study was designed to compare the efficacy, safety and certain health-related quality of life parameters of once-weekly selinexor in combination with once-weekly Velcade® (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade® plus low-dose dexamethasone (Vd). The primary endpoint of the study was progression-free survival (PFS) and key secondary endpoints included overall response rate (ORR), rate of peripheral neuropathy, and others. Additionally, the BOSTON study allowed for patients on the Vd control arm to crossover to the SVd arm following objective (quantitative) progression of disease verified by an Independent Review Committee (IRC). The BOSTON study was conducted at over 150 clinical sites internationally. Although the study had one of the highest proportions of patients with high-risk cytogenetics (~50%) as compared with other Velcade-based studies in previously treated myeloma, the median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio[HR]=0.70; p=0.0075). The SVd group also demonstrated a significantly greater ORR compared to the Vd group (76.4% vs. 62.3%, p=0.0012). Patients who had received only one prior line of therapy also demonstrated a higher ORR on the SVd arm as compared to the Vd arm (80.8% vs. 65.7%, p=0.0082). Importantly, SVd therapy compared to Vd therapy showed consistent PFS benefit and higher ORR across several important subgroups.In 2020, selinexor underwent a clinical trial for treatment of COVID-19.